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InvasionOur study focuses on a set of laryngeal tumors that show reduced RUNX3 expression in the absence
of transcriptional silencing of tumor suppressor gene RUNX3 by aberrant methylation of CpG
islands. We report that the loss of expression of RUNX3 correlates with up-regulation of miR-
106b in human laryngeal carcinoma tissue. The downregulation of RUNX3 is mediated by miR-
106b through binding of its 30UTR. Moreover, miR-106b can promote the proliferation and invasion
of laryngeal carcinoma cells by directly targeting RUNX3, and RUXN3 knockdown can abolish this
phenotype. These results shed a new insight into the mechanism of miRNA regulation in laryngeal
carcinoma.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Laryngeal carcinoma is a common head and neck malignancy
with high incidence because it accounts for approximately 2.4%
of new malignancies worldwide every year [1,2]. To further im-
prove its survival and cure rates, the carcinogenic mechanisms of
laryngeal carcinoma need to be elucidated.
Various genetic alterations associated with laryngeal carci-
noma, such as hTERT, CD24, PTEN, and RUNX1–3, have been de-
scribed [3–5]. RUNX3, which is located on chromosome 1p36,
has been identiﬁed as a critical tumour suppressor in many human
cancer types [6–11]. The loss of RUNX3 gene expression has been
reported to contribute to the tumourigenesis of many human tu-
mour types, including gastric cancers, colorectal cancers, breast
cancers, endometrial cancers, and laryngeal carcinomas [12–15].
The downregulation of RUNX3 has been mainly attributed to the
hypermethylation of its promoter region [10]. However, the results
of a previous study [16] demonstrated that there remains a propor-
tion of laryngeal carcinoma that shows reduced RUNX3 expression
in the absence of its methylation regulation mechanism, whichsuggests that other factors may be involved in the regulation of
RUNX3.
MicroRNAs (miRNAs) were recently characterised as endoge-
nous phylogenetically conserved small RNA molecules of approx-
imately 21–25 nucleotides in length that regulate target gene
expression by affecting the mRNA translation and stability or by
modulating the promoter activity of the target gene [17]. An
emerging body of evidence indicates that miRNAs play an impor-
tant role in a variety of pathogenic conditions, including cancer
[18,19]. A differential expression of miRNAs between tumour tis-
sues and normal tissues has been observed in various cancer types
[20], which suggests a possible link between miRNA expression
and the development of cancer. For example, the members of
the let-7 miRNA family have been found to be underexpressed
in lung cancer. The let-7 miRNA targets the oncogene RAS, and
the loss of let-7 expression results in the overexpression of RAS
[21]. In addition, miR-15 and miR-16 are downregulated in
chronic lymphocytic leukaemia and cause the overexpression of
the tumour suppressor gene BCL2, which protects cells from
apoptosis [22]. The aims of this study were to determine whether
the dysregulation of miRNAs that target RUNX3 in laryngeal car-
cinoma is responsible for the observed downregulation of RUNX3
and to evaluate the role of this mechanism in laryngeal
carcinoma.
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2.1. Clinical samples and cell lines
The 17 paired laryngeal carcinoma tissues used in this study
were obtained from The First Hospital of Shanxi Medical University
in China. The specimens, which included seven laryngeal carcino-
mas at stage I and II and seven laryngeal carcinomas at stage III
and IV, were snap-frozen in liquid nitrogen. The collection and
use of the patient samples were reviewed and approved by the
Institutional Ethics Committees, and written informed consent
was appropriately obtained from all of the patients. The Hep-2
and TU212 cells were purchased from ATCC.
2.2. Selection of candidate miRNAs
The candidate miRNAs that bind to RUNX3 were identiﬁed
using three web-based bioinformatics algorithms. TargetScan,
DIANA LAB, and microRNA predict miRNA-binding sites based on
the complementary nucleotide sequence in the 30-untranslated
region of the RUNX3 mRNA.
2.3. Luciferase reporter assay
The luciferase reporter assay was performed as described in the
Supplementary materials.
2.4. In vivo tumour xenograft studies
The tumorigenicity in nude mice was determined as described
previously [23,24], and the details of this procedure are described
in the Supplementary materials.Fig. 1. (A) Representative samples of MSP analysis. After bisulﬁte modiﬁcation, the prod
alleles of RUNX3 were loaded onto 2.5% agarose gels. (B) A Western blot assay was perfo
were normalised to those of GAPDH, and representative images are shown. (C) Immu
representative images from the four groups (normal laryngeal epithelium, adjacent lar
laryngeal carcinoma), are shown.2.5. Cell proliferation, colony formation, and invasion assays
The details of these procedures are described in the Supplemen-
tary materials.
2.6. Statistical analysis
The data are expressed as the means ± standard deviation (S.D.),
and differences that were found to have P < 0.05 using the Stu-
dents–Newman–Keuls test are considered statistically signiﬁcant.
All of the data were analysed with the SPSS 17.0 software to con-
ﬁrm their statistical signiﬁcance.
3. Results
3.1. The downregulation of RUNX3 in laryngeal carcinoma cells is
independent of DNA methylation
Twelve laryngeal carcinoma tissues were analysed by methyla-
tion-speciﬁc PCR (MSP) to detect the methylation status of the
RUNX3 CpG islands. As shown in Fig. 1A, tumours 2–4, 6, 9, 10,
and 11 were unmethylated at the RUNX3 CpG islands, whereas tu-
mours 1, 7, 8, and 12 were fully methylated at this locus. We then
determined the expression level of RUNX3 protein in these unme-
thylated and methylated laryngeal carcinoma tissues. The Western
blot results showed that the level of RUNX3 protein, which was
normalised to that of GAPDH, was always lower in laryngeal carci-
noma tissues compared to normal laryngeal epithelium, regardless
of the methylation status of the RUNX3 CpG islands (Fig. 1B). This
result was conﬁrmed with an immunohistochemistry assay. As
shown in Fig. 1C, RUNX3 exhibited a loss of expression in the lar-
yngeal carcinoma tissues compared to the normal laryngeal epi-ucts that were ampliﬁed with primers speciﬁc to the unmethylated or methylated
rmed to detect the RUNX3 protein levels in these tissues. The RUNX3 protein levels
nohistochemistry (IHC) was performed using anti-RUNX3 antibody to stain, and
ynx tissues, methylated RUNX3 laryngeal carcinoma, and non-methylated RUNX3
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These results suggest that RUNX3 is downregulated in laryngeal
carcinoma cells and that there is likely another potential mecha-
nism responsible for its downregulation.
3.2. miR-106b targets the RUNX3 transcript and downregulates its
expression
The TargetScan, microRNA, and DIANA LAB programs were se-
lected for the miRNA predictions. As shown in Fig. 2A, 11 candidate
miRNAs were identiﬁed. Of these, miR-130a/b and miR-301a/b
have been reported to target RUNX3 and regulate its expression
[25]. To determine which miRNA most effectively regulates
RUNX3, a luciferase reporter assay was performed. Hep2 cells were
transfected with a reporter vector and the 11 miRNAmimics. Obvi-
ously, miR-106b signiﬁcantly downregulated the luciferase inten-
sity of pGL3/luciferase-RUNX3-30-UTR (Fig. 2B). To further
determine whether miR-106b directly regulates RUNX3, another
luciferase reporter assay was used to validate the target site in
the RUNX3 30-UTR (Fig. 2C). Hep2 cells were transfected with the
reporter vector and miR-106b mimics, control mimics, ASO-miR-
106b, or control ASO. Interestingly, the intensity of luciferase in
the cells transfected with the miR-106b mimics was signiﬁcantly
decreased compared with the luciferase intensity of the controlFig. 2. (A) Schematic representation showing putative target site for miR-106b in RUNX
Cells were co-transfected with a luciferase construct (pGL3/luciferase/RUNX3-30-UTR) an
48 h after transfection and was normalised to that obtained in the control. (C) Luciferase c
The luciferase activity was determined 48 h after transfection. The ratio of the sensor nor
were transfected into Hep2 and TU-212 cells, and the RUNX3 protein level was measur
GAPDH bands. The fold changes in the RUNX3 expression were calculated using GAPDH a
of the data are expressed as the mean ± S.D. of three independent experiments. ⁄P < 0.05cells, whereas the intensity of luciferase in the cells transfected
with ASO-miR-106b was signiﬁcantly increased (Fig. 2C). In con-
trast, the luciferase intensity generated by the reporter vector con-
taining the mutant RUNX3 30-UTR was not affected by miR-106b
mimics or miR-106b ASO (Fig. 2C). These results indicate that
RUNX3 is a direct target of miR-106b. Moreover, we examined
the effect of miR-106b on the expression of endogenous RUNX3
by Western blot. The RUNX3 protein level was increased approxi-
mately three-fold in Hep2 and two-fold in TU-212 cells transfected
with ASO-miR-106b compared with the control group (Fig. 2D). In
addition, the RUNX3 protein level was decreased approximately
40% in Hep2 and 70% in TU-212 cells transfected with miR-106b
mimics compared with the control group (Fig. 2D).
3.3. miR-106b promotes the growth and invasion of human laryngeal
carcinoma cells
To determine the role of miR-106b in the proliferation and inva-
sion of laryngeal carcinoma cells, ASO-miR-106b was used to block
endogenous miR-106b expression in the Hep2 and TU-212 laryn-
geal carcinoma cell lines. The efﬁciency of the ASO-mediated
blocking of miR-106b was conﬁrmed by quantitative RT-PCR
(Fig. 3A). A colony formation assay and transwell invasion assay
were used to further elucidate the effect of miR-106b on the3 mRNA 30-UTR determined by the three miRNA target prediction algorithms’. (B)
d 17 miR mimics, including a control mimic. The luciferase activity was determined
onstructs were transfected into cells transduced with ASO-miR-106b and miR-106b.
malised to the control luciferase activity is shown. (D) miR-106b and ASO-miR-106b
ed. The Labwork4.0 software was used to quantify the intensity of the RUNX3 and
s the loading control. The level of RUNX3 in the control group was deﬁned as 1.0. All
compared with the control group.
Fig. 3. (A) ASO-miR-106b effectively blocks miR-106b expression in Hep2 and TU-212 cell lines, as determined by real-time PCR. The expression of miR-106b was normalised
to that of U6 RNA. (B) ASO-miR-106b treatment repressed the growth of xenograft laryngeal carcinoma derived from the introduction of Hep2 cells into SCID mice. The
images show the difference in the tumour sizes between the ASO-miR-346 group and the control group (statistically signiﬁcant, P < 0.05). (C) The blocking of miR-106b by
ASO affects the growth capacity of Hep2 and TU-212 cells, as determined by a colony formation assay. All of the histograms show the normalised mean percentages of colony
formation ± S.D. from three independent experiments. ⁄P < 0.05. (D) The blocking of miR-106b by ASO affects the invasion capacity of Hep2 and TU-212 cells, as determined
through a transwell invasion assay. The histograms show the normalised means of invading Hep2 or TU-212 cells ± S.D. from three independent experiments. ⁄P < 0.05. (E)
The expression of RUNX3 in the tumours of SCID mice treated with ASO-miR-106b and control ASO was measured by Western blot analysis, and the histograms show the
normalised mean of RUNX3 expression from ﬁve SCID mice in each group. ⁄P < 0.05.
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mation rate of Hep2 cells transfected with ASO-miR-106b was de-
creased approximately 50% compared with the control group
(Fig. 3C). The same phenomenon was observed in the TU-212 cells
(Fig. 3C). The transwell invasion assay indicated that the blocking
of miR-106b expression by ASO-miR-106b resulted in a lower de-
gree of invasion compared with that observed in the respective
Hep2 and TU-212 control cells (Fig. 3D). In addition, to determine
whether miR-106b is involved in tumorigenesis in vivo, a xenograft
tumour model in SCID mice was used. Because miR-106b promotes
the growth of laryngeal carcinoma cells, ASO-miR-106b was used
to generate a loss-of-function model. The average tumour volume
in mice treated with ASO-miR-106b was reduced approximately
70% compared with that observed in control mice (Fig. 3B). In addi-
tion, the RUNX3 protein expression level in the ASO-miR-106b-
treated tumours was increased approximately four-fold compared
with the control group (Fig. 3E). These results are consistent with
the effects of miR-106b on cultured laryngeal carcinoma cells
in vitro and strongly suggest that miR-106b promotes cell
growth and that its downregulation represses laryngeal carcinoma
growth.3.4. The overexpression of RUNX3 represses the cell growth and
invasion of Hep2 and TU-212 cells, and the knockdown of RUNX3
abrogates the ASO-miR-106b-induced suppression of Hep2 and TU-
212 cell growth and invasion
To determine the inﬂuence of RUNX3 on the growth of Hep2
cells, RUNX3 was overexpressed using an RUNX3 expression plas-
mid (pCMV6/RUNX3). The Western blot assay showed that
pCMV6/RUNX3 effectively increased the expression of RUNX3
approximately three-fold in Hep2 cells and two-fold in TU-212
cells compared with the control cells (Fig. 4A). The growth curve
assay indicated that the overexpression of RUNX3 resulted in a
slower growth than that observed in the control Hep2 and TU-
212 cells (Fig. 4B). A colony formation assay was then performed
to evaluate the effect of the overexpression of RUNX3 on the
growth of Hep2 cells. The colony formation rate of the cells trans-
fected with the pCMV6/RUNX3 vector was markedly lower than
that observed in the control group (Fig. 4C). In addition, the trans-
well invasion assay indicated that the overexpression of RUNX3 by
pCMV6/RUNX3 resulted in a lower level of invading cells than that
observed in the respective Hep2 and TU-212 control cells (Fig. 4D).
Fig. 4. (A) Western blot assays show that pCMV6/RUNX3 increased the RUNX3 protein levels compared with the control group in Hep2 and TU-212 cells. ⁄P < 0.05. (B)
Growth curves of Hep2 and TU-212 cells transfected with pcMV6/RUNX3 and control vector. At 48 h post-transfection, 4000 cells were seeded in 24-well plates and counted
daily over a period of 6 days. The cell viability was determined by the OD value. (C) RUNX3 suppresses the growth of Hep2 and TU-212 cells, as determined through a colony
formation assay. All of the histograms show the normalised mean percentages of colony formation ± S.D. from three independent experiments. ⁄P < 0.05. (D) The
overexpression of RUNX3 by pCMV6/RUNX3 affects the invasion capacity of Hep2 and TU-212 cells, as determined by a transwell invasion assay. The histograms show the
normalised mean of invading Hep2 or TU-212 cells ± S.D. from three independent experiments. ⁄P < 0.05. Representative pictures are shown above the histograms. (E) The
expression levels of TIMP-1, cdk2, cdk4, Rb, and p27 proteins were evaluated in Hep2-control and Hep2-pCMV6/RUNX3 and in TU-212-control and TU-212-pCMV6/RUNX3
cells by Western blot. All of examined expression levels were normalised to that of GAPDH.
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suppression partially regulated various proteins, including inhibit-
ing cdk2 and cdk4 and increasing p27, Rb, and TIMP-1. Thus, we
also determined the effect of RUNX3 overexpression on the expres-
sion of its downstream genes in laryngeal carcinoma cell lines, and
the Western blot results conﬁrm that the RUNX3 overexpression
vector was effective and exhibits a homogeny function. These re-
sults indicate that the knockdown of RUNX3 repressed the growth
and invasion of Hep2 and TU-212 cells.
To verify whether miR-106b promotes the proliferation and
invasion of Hep2 cells and TU-212 cells by regulating RUNX3, an
RUNX3 knockdown vector (RUNX3-siRNA) was designed to reduce
the RUNX3 protein level. This vector, which does not affect the
expression of miR-106b in transfected laryngeal carcinoma cells
(Fig. 5A), was used to rescue the suppressive effect of the knock-
down of miR-106b on Hep2 and TU-212 cell growth and invasion.
When Hep2 and TU-212 cells were cotransfected with ASO-miR-
106b and either RUNX3-siRNA or a control vector, the inhibition
of the colony formation rate and cell invasion viability caused by
ASO-miR-106b was counteracted by the knockdown of RUNX3but not by a control vector (Fig. 5C and D). Western blot assays
showed that the RUNX3 expression was also rescued (Fig. 5B).
These results indicate that RUNX3 is a downstream target gene
of miR-106b and is involved in the miR-106b-mediated promotion
of cell growth and invasion in the Hep2 and TU-212 laryngeal car-
cinoma cell lines.
3.5. The RUNX3 expression level is inversely correlated with the miR-
106b level in human laryngeal carcinoma tissues
All of above results suggest that miR-106b can promote the
growth and invasion in the Hep2 and TU-212 laryngeal carcinoma
cell lines by directly targeting RUNX3. To determine whether this
regulation axis exists in larynx cancer tissues, we examined the le-
vel of miR-106b and RUNX3 in 14 human larynx cancer tissues.
miR-106b was detected by real-time PCR, and RUNX3 was detected
by Western blot. As shown in Fig. 6A and B, the expression of miR-
106b was inversely correlated with the expression of RUNX3 in the
examined larynx cancer tissues. The comparison of the larynx can-
cer tissues and matched normal tissues showed that miR-106b is
Fig. 5. (A and B) The expression levels of miR-106b and RUNX3 were measured by real-time PCR and Western blot, respectively, in each group of transfected Hep2 and TU-
212 cells. (C and D) RUNX3 siRNA counteracts the growth inhibition and invasion of Hep2 and TU-212 cells caused by ASO-miR-106b compared with that observed in control
cells. The cell growth capacity of Hep2 and TU-212 cells transfected with ASO-miR-106b and siRNA-RUNX3 or with ASO-miR-106b and siRNA control was detected by colony
formation assays. The cell invasion capacity of Hep2 and TU-212 cells was determined through transwell invasion assays. ⁄P < 0.05.
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which indicates that the miR-106/RUNX3 axis may play an impor-
tant role in the process of larynx cancer tumorigenesis.
4. Discussion
An increasing body of evidence indicates that the miRNA repres-
sion of tumour suppressor genes may be a common mechanism in-
volved in the tumourigenesis of laryngeal carcinoma, including the
regulation of Rb by miR-106b [26]. In fact, an increasing number of
miRNAs have been linked to the development of laryngeal carci-
noma. These identiﬁed miRNAs target the expression of a diverse
set of genes, e.g., miR-21 targets PTEN, miR-203 targets survivin,
miR-24 targets S100A8, miR-206 targets VEGF, miR-16 targets Zyx-
in,miR-1 targets ﬁbronectin1, andmiR-34c targets c-Met [5,27–32].
As an important tumour suppressor, the expression of RUNX3 is
lost in gastric cancer cell lines and in various types of humancancers, including laryngeal carcinoma, and this loss is mostly
accompanied by the aberrant methylation of its promoter
[16,33]. Kim et al. reported the RUNX3 methylation rate in 37 lar-
ynx tumour tissues was 62%. In contrast, 38% of these laryngeal
carcinoma tissues may have a lower expression level of RUNX3
without DNA methylation. Indeed, Lai et al. claimed that there ex-
ists a mechanism of miR-130b-induced RUNX3 downregulation in
gastric cancer tumorigenesis. In this study, we ﬁrst determined the
RUNX3 methylation status and evaluated its expression level in
methylated and non-methylated laryngeal carcinoma tissues. Our
results demonstrated that RUNX3 is always downregulated both
in the methylated and in the non-methylated laryngeal carcinoma
tissues (Fig. 1). To explore whether the mechanism of miRNA-med-
iated suppression of tumour suppressors contributes to the loss of
RUNX3 expression in both methylated and non-methylated laryn-
geal carcinoma, a bioinformatics approach was used to predict
miRNAs that might bind to the RUNX3 30-UTR. Based on the results
Fig. 6. The expression of miR-106b was determined by real-time PCR in 14 paired human laryngeal carcinoma tissues and normalised to the level of U6 RNA. The data are
expressed as the mean ± S.D. of three independent experiments. ⁄P < 0.05 compared with the control group. The expression level of RUNX3 in 14 paired laryngeal carcinoma
tissues was measured by Western blot using the anti-RUNX3 antibody described in Section 2.3 and was normalised to the level of GAPDH.
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most putative candidates for the study of the miRNA regulation of
RUNX3 (Fig. 2A). The subsequent luciferase assay (Fig. 2B) showed
that miR-106 signiﬁcantly decreased the luciferase activity of
pGL3/luciferase-RUNX3-30-UTR. Thus, a functional validation and
assessment of miR-106b in laryngeal carcinoma cell lines and clin-
ical samples was then performed (Fig. 2C and D, Fig. 6).
miR-106b, which is located on chromosome 7, has been re-
ported to participate in the development and progression ofhuman tumours, such as hepatocellular cancer, prostate cancer,
gastric cancers, and renal cell carcinoma [34–37]. In our study,
the repression of miR-106b resulted in the inhibition of laryngeal
carcinoma cell proliferation and invasion (Fig. 3). This phonotype
of laryngeal carcinoma cells regulated by miR-106b was partly
attributed to the miR-106b-induced downregulation of RUNX3
through targeting of the 30-UTR of RUNX3. The rescue assays per-
formed in this study demonstrated that miR-106b downregulated
the expression of RUNX3 directly because the knockdown of
Y. XU et al. / FEBS Letters 587 (2013) 3166–3174 3173RUNX3 abolished the miR-106b-ASO-mediated inhibition of laryn-
geal carcinoma cell proliferation and invasion (Fig. 5). A previous
study had reported that miR-106b promotes cell proliferation by
targeting Rb in laryngeal carcinoma [26]. In this study, we evi-
denced that RUNX3 is a novel direct and functional target of
miR-106b that is involved in the proliferation of laryngeal carci-
noma cells.
It has been proposed that a single miRNA can target several
genes and that multiple miRNAs can target a single gene in a com-
prehensive manner [38,39]. Several studies have reported that a
single miRNA can regulate the growth, invasion, migration, and cell
cycle arrest laryngeal carcinoma cells by directly targeting a single
gene [5,27–32]; this type of system is called a one-miRNA-targets-
one-gene model. Based on the results reported by Cai et al., we
found a new model, which we called a one-miRNA-targets-two-
genes model, in laryngeal carcinoma. In this model, miRNA-106b
regulates laryngeal carcinoma cell growth and invasion by target-
ing two tumour suppressors, RUNX3 and Rb (Fig. 7). Additionally,
RUNX3 can positive regulate the expression of Rb in renal cell car-
cinoma (RCC) [40]. Thus, this one-target-two model exhibits posi-
tive feedback regulation in laryngeal carcinoma and thus acts as an
advanced regulatory mechanism in laryngeal carcinoma cells. This
ﬁnding may have important implications for the development of
future therapies for the treatment of laryngeal carcinoma.
In conclusion, our study has several major ﬁndings. (a) RUNX3
is downregulated in laryngeal carcinoma irrespective of the meth-
ylation status of its CpG region. (b) This study provides the ﬁrst
demonstration that miR-106b directly targets RUNX3 and down-
regulates the expression of RUNX3 in laryngeal carcinoma cells.
(c) The suppression of miR-106b causes a marked inhibition of pro-
liferation and invasion in the laryngeal carcinoma Hep2 and TU-
212 cell lines, and this phenotype can be rescued by the knock-
down of RUNX3. (d) miR-106b regulates laryngeal carcinoma cell
growth and invasion in a one-miRNA-targets-two-genes manner,
which involves a positive feedback regulation mechanism. (e) In
clinical laryngeal carcinoma tissues, the expression level of miR-
106b and RUNX3 exhibit a signiﬁcant inverse correlation. These re-
sults provide strong evidence that RUNX3 can also be inactivated
in laryngeal carcinoma cells by miRNA expression in addition to
hypermethylation. Further studies are required to determineFig. 7. Schematic representation of the hypothetical molecular mechanism through
which miRNAs regulate the growth, invasion, migration, and cell cycle of laryngeal
carcinoma cells. Two models are described: the one-miRNA-targets-one-gene
model and the one-miRNA-targets-two-genes model. In addition, miR-106b,
RUNX3, and Rb are involved in a positive feedback regulation that may contribute
to the tumourigenesis of laryngeal carcinoma.whether the miR-106b-target-RUNX3 mechanism contributes to
the tumourigenesis of other cancers.
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